Article

Constraint-Induced Movement therapy (CIMT) has controlled evidence of
efficacy for improving real-world paretic limb use in non-progressive physically
disabling disorders (stroke, cerebral palsy). OBJECTIVE:
This study sought to
determine whether this therapy can produce comparable results with a progressive
disorder such as multiple sclerosis (MS). We conducted a preliminary phase II
randomized controlled trial of CIMT versus a program of complementary and
alternative medicine (CAM) treatments for persons with MS, to evaluate their
effect on real-world disability. METHODS: Twenty adults with hemiparetic MS
underwent 35 hours of either CIMT or CAM over 10 consecutive weekdays. The
primary clinical outcome was change from pretreatment on the Motor Activity Log
(MAL). RESULTS: The CIMT group improved more on the MAL (2.7 points, 95%
confidence interval 2.2-3.2) than did the CAM group (0.5 points, 95% confidence
interval -0.1 to 1.1; P < .001). These results did not change at 1-year
follow-up, indicating long-term retention of functional benefit for CIMT. The
treatments were well tolerated and without adverse events. CONCLUSION: These
results suggest that CIMT can increase real-world use of the more-affected arm in
patients with MS for at least 1 year. CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov NCT01081275.

Langue : ANGLAIS